TMEM180 Inhibitors
TMEM180 inhibitors represent a class of chemical compounds designed to selectively interact with the transmembrane protein 180 (TMEM180). TMEM180 is a protein that is embedded within the cell membrane and is implicated in various cellular processes due to its structural and functional properties. Inhibitors targeting TMEM180 are specialized molecules that can bind to this protein, affecting its function by altering its conformation or by steric hindrance, which in turn can influence the protein's ability to participate in its normal biological activities. The design of TMEM180 inhibitors is based on the understanding of the protein's structure and the essential domains that are crucial for its activity. By binding to these specific regions, TMEM180 inhibitors are able to modulate the protein's behavior within the cellular environment.
The development of TMEM180 inhibitors involves an intricate process of chemical synthesis and molecular engineering. This process takes into account the physicochemical properties of TMEM180, such as the hydrophobic and hydrophilic regions of the protein, to ensure that the inhibitors have both a high affinity for their target and suitable pharmacokinetic properties. The interaction between TMEM180 inhibitors and the protein can be characterized through various biochemical and biophysical techniques, which help elucidate the binding kinetics and the specificity of inhibition. Advanced computational methods, including molecular docking and dynamic simulations, often play a pivotal role in the initial stages of inhibitor design by predicting how these molecules might interact with the protein at an atomic level. Subsequent experimental validation in biochemical assays helps to confirm these predictions and refine the inhibitor molecules for enhanced selectivity and potency.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor. By blocking EGFR, it inhibits downstream signaling pathways that can regulate the expression of various genes, including those that may code for transmembrane proteins such as TMEM180, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to the FKBP12 protein to form a complex that inhibits the mTOR (mammalian target of rapamycin) pathway. Inhibition of mTOR can downregulate protein synthesis, including the synthesis of proteins like TMEM180 that may be involved in cellular proliferation and survival. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor, which impedes the PI3K/AKT/mTOR signaling pathway. This can lead to a reduction in the synthesis of proteins implicated in cell growth and survival, potentially decreasing the levels and activity of TMEM180. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor, which prevents the activation of the MAPK/ERK pathway. This pathway is often involved in the regulation of gene expression and protein synthesis. By inhibiting MEK, U0126 could indirectly suppress the expression of TMEM180. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that can block the PI3K/AKT signaling pathway, possibly resulting in decreased expression and activity of proteins such as TMEM180. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which blocks the MAPK/ERK pathway. By inhibiting this pathway, PD98059 can indirectly lead to reduced expression of proteins like TMEM180, which may be under the control of this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which can disrupt the p38 MAPK signaling pathway. This pathway is involved in stress responses and inflammation, and inhibition by SB203580 could reduce the expression of related proteins, including TMEM180. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. JNK inhibition can alter transcriptional regulation, potentially decreasing the expression of proteins such as TMEM180. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is another EGFR inhibitor that can block downstream signaling pathways which regulate gene expression. This can lead to a reduction in the synthesis of proteins like TMEM180. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can disrupt the degradation of regulatory proteins, leading to altered signaling and potentially decreased synthesis of proteins including TMEM180. | ||||||